Taking the opposite approach of targeted protein degradation, biotech company Entact Bio is developing medicines that stabilize proteins and even enhances their function. This approach that could apply to cancer and certain rare diseases and Entact's $81 million in Series A financing enables it to work on multiple programs in parallel.
/PRNewswire/ Polaris Market Research recently published [115+ Pages] research report on "Protein Expression Market Share, Size, Trends, Industry Analysis.
Tech Transfer Roundup: Erasca Calls On MD Anderson To Advance Its RAS/MAPK Pipeline informa.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from informa.com Daily Mail and Mail on Sunday newspapers.